24 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
Are You Looking for a Top Momentum Pick? Why Merck (MRK) is a Great Choice http://www.zacks.com/stock/news/432232/are-you-looking-for-a-top-momentum-pick-why-merck-mrk-is-a-great-choice?cid=CS-ZC-FT-432232 Jun 20, 2019 - Does Merck (MRK) have what it takes to be a top stock pick for momentum investors? Let's find out.
Stock Market News For Jun 20, 2019 http://www.zacks.com/stock/news/432206/stock-market-news-for-jun-20-2019?cid=CS-ZC--432206 Jun 20, 2019 - Wall Street closed higher on Wednesday after the Fed kept the federal fund target rate unchanged.
Pharma Stock Roundup: PFE to Buy ARRY, RHHBY, MRK, AZN Drugs Get Regulatory Nod http://www.zacks.com/stock/news/432688/pharma-stock-roundup-pfe-to-buy-arry-rhhby-mrk-azn-drugs-get-regulatory-nod?cid=CS-ZC-FT-432688 Jun 21, 2019 - Pfizer (PFE) announces definitive deal buy Array BioPharma. Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) win approvals for new drugs/line extensions.
Dow 30 Stock Roundup: Boeing's $6.5B Air Force Contract, Pfizer to Buy Array BioPharma http://www.zacks.com/stock/news/432790/dow-30-stock-roundup-boeings-%2465b-air-force-contract-pfizer-to-buy-array-biopharma?cid=CS-ZC-FT-432790 Jun 21, 2019 - The index enjoyed another week of strong gains after the Federal Reserve indicated that a rate cut would likely occur next month.
Is the FDA Out to Get This $2.9 Billion Diabetes Drug Class? https://www.fool.com/investing/2019/09/05/is-the-fda-out-to-get-this-29-billion-diabetes-dru.aspx?source=iedfolrf0000001 Sep 05, 2019 - It’s rejected a pair of drugs in the last six months.
Endo Gains FDA Nod for Orfadin Generic to Treat Rare Disease http://www.zacks.com/stock/news/503280/endo-gains-fda-nod-for-orfadin-generic-to-treat-rare-disease?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-503280 Sep 05, 2019 - Endo (ENDP) receives an FDA approval for the generic equivalent of Swedish Orphan Biovitrum's Orfadin.
AstraZeneca's Tagrisso Gets Nod in China for First-Line NSCLC http://www.zacks.com/stock/news/503575/astrazenecas-tagrisso-gets-nod-in-china-for-first-line-nsclc?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-503575 Sep 05, 2019 - AstraZeneca's (AZN) Tagrisso gets a marketing approval in China for the first-line treatment of advanced or metastatic non-small cell lung cancer in patients with tumors having EGFR mutations.
Buy 5 Top Dow Stocks to Gain From Index's Rally http://www.zacks.com/stock/news/510834/buy-5-top-dow-stocks-to-gain-from-indexs-rally?cid=CS-ZC-FT-analyst_blog|investment_ideas-510834 Sep 10, 2019 - The Dow is expected to maintain its current momentum for the rest of this month and further due to two immediate catalysts.
4 Big Drugmakers Boasting Impressive Oncology Pipelines http://www.zacks.com/stock/news/513001/4-big-drugmakers-boasting-impressive-oncology-pipelines?cid=CS-ZC-FT-analyst_blog|industry_focus-513001 Sep 11, 2019 - We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.
Roche's New Perjeta Combo Meets Goal in Breast Cancer Study http://www.zacks.com/stock/news/517413/roches-new-perjeta-combo-meets-goal-in-breast-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-517413 Sep 13, 2019 - Roche's (RHHBY) new fixed-dose combination of Perjeta and Herceptin meets the primary endpoint in the phase III study for treating patients with HER2-positive early breast cancer.

Pages: 123

Page 1>